ICON Central Laboratories Launches iSite Portal for Investigator Sites
ICON plc
(NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of
iSite
, a secure web-based portal that drives efficiency by providing investigators 24-hour access to study-specific laboratory information from
ICON Central Laboratories
.
iSite
is an easy-to-use portal that allows investigators and other site personnel to access electronic laboratory reports for their active studies at any time. It includes user-friendly navigation, filtering and report management and provides investigators customised views of reports by study, site, subject or visit date. iSite also includes email alert functionality which notifies investigators when new reports become available.
“We are continuously looking to introduce innovative technology solutions that drive efficiency and improve performance,” commented
Tom O’Leary
, President, ICON Central Laboratories. “iSite provides investigators a much needed solution for accessing important study-specific information in the most rapid, secure and convenient way possible.”
A future release of iSite is in development and will provide sites with study-specific performance metrics and additional tools such as customised electronic laboratory manuals which will be created by ICON’s
Firecrest™ technology
. ICON’s Firecrest delivers an innovative suite of training and study management tools which can significantly improve the compliance, consistency and execution of study-related activities at investigator sites.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
